NDAORALTABLETPriority Review
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
47
Data completeness
6/8 — Strong
Priority Review
TUKYSA (tucatinib) by Pfizer is tyrosine kinase inhibitors [moa]. Approved for her2-positive breast cancer, metastatic breast cancer. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TUKYSA (tucatinib) is an oral tyrosine kinase inhibitor approved by the FDA on April 17, 2020, developed by Pfizer. It is designed to inhibit HER2-mediated signaling pathways in cancer treatment. As a selective kinase inhibitor, TUKYSA fits into the precision oncology treatment landscape for HER2-positive malignancies. The product is currently in its peak lifecycle stage.
$0.1BPart D
12.0 years to LOEMechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (2)
Worked on TUKYSA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.